The FDA has approved a new formulation for prostate cancer imaging, with the product referred to as Pylarify TruVu or piflufolastat F 18. This approval appears to be related to a PSMA-PET imaging agent, although details of the formulation and its uses are not entirely clear. The approval is associated with Lantheus, which has announced the development, although the status of the approval process was not consistently reported across outlets.